Human T leukaemia Type 1 and COVID-19
Open Access
- 3 June 2020
- Vol. 9 (6), 438
- https://doi.org/10.3390/pathogens9060438
Abstract
In the absence of clinical data on Human T leukaemia Type 1 and COVID-19 infection, we are providing guidance to clinicians who look after people living with HTLV-1.This publication has 14 references indexed in Scilit:
- Human T-Lymphotropic Virus type 1c subtype proviral loads, chronic lung disease and survival in a prospective cohort of Indigenous AustraliansPLoS Neglected Tropical Diseases, 2018
- The Exceptional Oncogenicity of HTLV-1Frontiers in Microbiology, 2017
- HTLV-1 drives vigorous clonal expansion of infected CD8+ T cells in natural infectionRetrovirology, 2015
- Inflammatory manifestations of HTLV-1 and their therapeutic optionsExpert Review of Clinical Immunology, 2014
- Human T Cell Lymphotropic Virus (HTLV) Type–1–Specific CD8+T Cells: Frequency and Immunodominance HierarchyThe Journal of Infectious Diseases, 2004
- Human T Cell Lymphotropic Virus Type I (HTLV-I)-Specific CD4+ T Cells: Immunodominance Hierarchy and Preferential Infection with HTLV-IThe Journal of Immunology, 2004
- Diagnostic criteria and classification of clinical subtypes of adult T‐cell leukaemia‐lymphomaBritish Journal of Haematology, 1991
- Pulmonary Involvement in Patients with HTLV-I-associated Myelopathy: Increased Soluble IL-2 Receptors in Bronchoalveolar Lavage FluidAmerican Review of Respiratory Disease, 1989
- Suppression of tuberculin skin reaction in healthy HTLV‐I carriers from JapanInternational Journal of Cancer, 1988
- Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphomaProceedings of the National Academy of Sciences of the United States of America, 1980